MCM
UTHR icon

Manchester Capital Management’s United Therapeutics UTHR Stock Holding History

Manchester Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.17K Hold
4
– – ﹤0.01% 1030
2026
Q1 		$2.37K Hold
4
– – ﹤0.01% 990
2025
Q4 		$1.95K Buy
+4
New +$1.86K ﹤0.01% 1026
2014
Q2 		– Sell
-2,669
Closed -$251K – 1107
2014
Q1 		$251K Sell
2,669
-4,124
-61% -$422K 0.04% 279
2013
Q4 		$768K Hold
6,793
– – 0.12% 91
2013
Q3 		$536K Hold
6,793
– – 0.09% 118
2013
Q2 		$447K Buy
+6,793
New +$438K 0.08% 135

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Manchester Capital Management's UTHR Position: Q2 2026 in Review

Manchester Capital Management held its United Therapeutics (UTHR) position steady in Q2 2026 at 4 shares worth $2.17K. The position accounts for ﹤0.01% of the portfolio, ranked #1030.

Manchester Capital Management first reported a position in UTHR in Q2 2013 and has held it in 7 quarters since. The position peaked at $768K in Q4 2013. 882 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Manchester Capital Management held 4 shares of United Therapeutics worth $2.17K as of Q2 2026.
  • Manchester Capital Management left its United Therapeutics share count unchanged in Q2 2026.
  • United Therapeutics made up ﹤0.01% of Manchester Capital Management's portfolio in Q2 2026, its #1030 holding.
  • Manchester Capital Management first reported a position in United Therapeutics in Q2 2013 and has held it in 7 quarters since.
  • Manchester Capital Management's United Therapeutics position peaked at $768K in Q4 2013.
  • 882 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Manchester Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.